Share on LinkedInShare on LinkedIn

ARTICLE · 19 MARCH 2018

Apotex Released From Infringement Finding After Claim Construction Appeal

Second, the Federal Circuit's construction specifies that the extended release coating be a continuous film.

United StatesIntellectual Property

The US Court of Appeals for the Federal Circuit found that the US District Court for the District of Delaware erred in its claim construction and consequently vacated the ruling that Apotex's proposed abbreviated new drug application (ANDA) product infringed Aptalis/Ivax's asserted patent claiming an extended release form of the muscle relaxant cyclobenzaprine hydrochloride. Aptalis Pharmatech, Inc. v. Apotex Inc., et al., Case No. 2017-1344 (Fed. Cir., Jan. 4, 2018) (Stoll, J).

Aptalis and Ivax own US Patent Nos. 7,790,199 and 7,829,121, which are Orange Book-listed for AMRIX®, approved for treating muscle spasms. Apotex filed an ANDA seeking to market a generic version of the product prior to patent expiry. 

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from